Experimental CAR-T therapy takes on stubborn cancers
NCT ID NCT06937567
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-phase trial tests a new cell therapy called UCLH80-1 in 36 people with advanced solid tumors (colorectal, gastric, pancreatic, and bile duct cancers) that have not responded to standard treatments. The therapy uses specially engineered immune cells to target a protein called CDH17 found on cancer cells. The main goal is to check safety and find the right dose, while also looking for any signs that the tumors shrink.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- UCLH80-1 CAR-T cells (a type of immune cell therapy targeting CDH17)
- What this could lead to
- If it works, this could point toward a new treatment option for several hard-to-treat cancers like colorectal, gastric, and pancreatic cancer.
- What could go wrong
- This is a very early (Phase 1) trial with only 36 participants, so it is primarily checking safety. The therapy may not shrink tumors, and there are risks like severe immune reactions or organ damage.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BILIARY TRACT CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
The First Affiliated Hospital Zhejiang University School of Medicine
RECRUITINGHangzhou, Zhejiang, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a plasma beam stop colon polyps from coming back?
- A stitch in time: could a device make abdominal closure safer?
- Can we predict chemo brain before it happens?
- Your gut bacteria might reveal hidden cancer risk
- Can a smart digital program restore sleep for cancer survivors?
- Can a new infusion drug shrink Hard-to-Treat tumors?